CLDX, US15117B2025

Celldex reports Phase 3 success as HC Wainwright rates Celldex Therapeutics stock Buy

Published on 10/07/2026 at 01:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Week 12 complete responses reached 42.40 percent versus 9.30 percent on placebo. Celldex Therapeutics stock cost EUR 27.54 on October 6, 2026 after EUR 27.54.

CLDX, US15117B2025, Illustration mit AI erstellt.

Celldex Therapeutics (ISIN US15117B2025) reported positive Phase 3 results for barzolvolimab on September 22, 2026, while MarketBeat reported on October 2, 2026, that HC Wainwright reaffirmed a Buy rating and a USD 64.00 price objective for Celldex Therapeutics stock.

Phase 3 results show a clear response gap

According to StockTitan, the EMBARQ-CSU1 and EMBARQ-CSU2 studies met their primary and key secondary endpoints at Week 12. In EMBARQ-CSU1, complete response reached 42.40 percent with barzolvolimab 150 mg every four weeks, compared with 9.30 percent for placebo.

The trial program enrolled 1,939 patients, giving the result a broad clinical base. In the omalizumab-refractory subgroup, the 150 mg dose produced a 55.30 percent complete response rate at Week 12, versus 9.30 percent for placebo in EMBARQ-CSU1.

Clinical progress meets financial pressure

The commercial case remains dependent on development execution. Celldex said the Phase 3 studies continue through 52 weeks and plans to submit a Biologics License Application in 2027, as reported in the September 22, 2026 filing carried by StockTitan.

Celldex's second-quarter 2026 financial results show the cost of that pipeline strategy. Markets Insider reported quarterly revenue of USD 22,000 and a GAAP net loss of USD 73.50 million for the quarter ended June 30, 2026, compared with USD 730,000 of revenue and a USD 56.60 million loss a year earlier.

Analyst targets remain widely separated

MarketBeat reported HC Wainwright's USD 64.00 target, while Markets Insider said Goldman Sachs maintained a Hold rating and set a USD 28.00 target on October 5, 2026. The USD 36.00 gap between those targets underscores how heavily valuation depends on the clinical and regulatory path.

The last euro quote was EUR 27.54

The last Lang & Schwarz quote for Celldex Therapeutics was EUR 27.54 on October 6, 2026 at 10:59 p.m. CEST, matching the prior close of EUR 27.54 for that session. The primary listing is Nasdaq, where the finance quote showed USD 31.00 at 4:00 p.m. ET on October 6, 2026, down 4.86 percent from USD 32.59; the 52-week range was USD 22.10 to USD 45.14 and market capitalization was USD 2.1 billion.

The further course of trading is shown by the continuously updated real-time quote of Celldex Therapeutics stock.